

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 July 2006 (20.07.2006)

PCT

(10) International Publication Number
WO 2006/076009 A3

(51) International Patent Classification:

A01N 43/50 (2006.01) A61K 31/415 (2006.01)

(21) International Application Number:

PCT/US2005/014345

(22) International Filing Date: 25 April 2005 (25.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/565,047	23 April 2004 (23.04.2004)	US
60/569,032	7 May 2004 (07.05.2004)	US
60/623,251	28 October 2004 (28.10.2004)	US

(71) Applicant (for all designated States except US):
PARATEK PHARMACEUTICALS, INC. [US/US]; 75
Kneeland Street, Boston, Massachusetts 02111 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALEKSHUN, Michael N.** [US/US]; 32 Eustis Avenue, Wakefield, Massachusetts 01880 (US). **AMOO, Victor** [US/US]; 8176 Palmetto Court, Daphne, Alabama 36526 (US).

KIM, Oak K. [US/US]; 86 Ellery Street, #1, Cambridge, Massachusetts 02138 (US). **VERMA, Atul K** [IN/US]; 3 Brian Lane, Mansfield, Massachusetts 02048 (US).


(74) Agents: **HANLEY, Elizabeth A.** et al.; Lahive & Cockfield, LLP, One Post Office Square, Boston, MA 02109-2127 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF



(57) Abstract: Substituted benzimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzimidazole compounds, as well as pharmaceutical preparations therefore, in, e.g., reducing antibiotic resistance and inhibiting biofilms.



WO 2006/076009 A3



Published:

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(88) Date of publication of the international search report:

27 December 2007

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 05/14345

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A01N 43/50; A61K 31/415 (2007.01)

USPC - 514/396

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
USPC-514/396Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
USPC- 235.8, 385, 393-395 (see search terms below)Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Google: terms-N-hydroxy benzimidazole composition, 2-phenyl benzimidazole composition, benzimidazole 2-carboxamide composition, transcription modulating, antibiotic resistance and transcription modulating.
WEST

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2004/001058 A2 (Levy et al.) 31 December 2003 (31.12.2003), entire document	1-3, 5, 7, 9, 16, 18, 35, 37, 62, 64 and 78
Y	US 6,204,264 B1 (Kobayashi et al.) 20 March 2001 (20.03.2001), entire document, especially Claims 1-9; p 58, ln 28-30	1-3, 5, 7, 9, 16, 18, 35, 37, 62, 64 and 78
Y	US 6,348,487 B1 (Connor et al.) 19 February 2002 (19.02.2002), entire document, especially col 35-40	3, 5, 7, 9, 16, 18, 35, 37, 62, 64 and 78



Further documents are listed in the continuation of Box C.



* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

9 August 2007 (09.08.2007)

Date of mailing of the international search report

25 SEP 2007

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 05/14345

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 10-15, 19-34, 38-61, 65-77 and 79-96
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

-- see continuation sheet --

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Group I: claims 1-3, 5, 7, 9 (limited to antibiotic resistance), 16, 18 (limited to antibiotic resistance), 35, 37 (limited to antibiotic resistance), 62, 64 and 78 (limited to antibiotic resistance), directed to methods of reducing antibiotic resistance.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.